Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,727.44
+14.660.86%
Number of Gainers:5
Number of Losers:2
Number of Flat:- -
PE:- -
High:1,745.93
Open:1,710.27
Low:1,697.28
Close:1,712.79
Volume:60.92M
Turnover:5.75B
Market Cap:1.80T
Float Cap:1.73T

Loading ...

Pfizer’s Quiet Trial Wave Hints at Big Pipeline Upside

TIPRANKS
·
Yesterday

Is The Depo-Provera Meningioma Settlement Reshaping Legal Risk In Pfizer’s Investment Case (PFE)?

Simply Wall St.
·
Yesterday

Funds: What a Top Biotech Fund is Buying Now

Dow Jones
·
Yesterday

Novavax Inc. Stock Rises 6.2%, Outperforms Peers

Dow Jones
·
Yesterday

Amgen Advances Tarlatamab Shot vs. Infusion in Phase 3 Lung Cancer Study

TIPRANKS
·
Yesterday

Eli Lilly Targets Ramadan Diabetes Market With New Orforglipron Trial

TIPRANKS
·
Yesterday

Pfizer’s India Migraine Study Adds Real-World Momentum for PFE

TIPRANKS
·
Yesterday

Pfizer’s Real World Prostate Cancer Study Sets Up a New Test for Leading Therapies

TIPRANKS
·
Yesterday

Eli Lilly’s Dulaglutide Study Sheds Light on Fasting Risks and Diabetes Care

TIPRANKS
·
Yesterday

Pfizer’s Atirmociclib Study Marks Quiet but Important Step in Pipeline Progress

TIPRANKS
·
Yesterday

Novo Nordisk A/S Series B Stock Rises Friday, Outperforms Market

Dow Jones
·
Yesterday

Analysts Have Conflicting Sentiments on These Healthcare Companies: Innoviva (INVA) and Pfizer (PFE)

TIPRANKS
·
Aug 21

Pharma Stocks Have Rallied. 2 Stocks to Avoid-and 2 to Buy.

Dow Jones
·
Aug 21

Cboe data shows mixed options sentiment in Pfizer with shares down 1.5%

TIPRANKS
·
Aug 21

Eli Lilly Advances Early-Stage Eloralintide Trial: What Investors Should Watch

TIPRANKS
·
Aug 21

Pfizer’s Ibrance Real-World Breast Cancer Study Wraps Up: What Investors Should Watch Next

TIPRANKS
·
Aug 21

Eli Lilly’s Lebrikizumab Trial Completion Signals New Growth Path in Atopic Dermatitis

TIPRANKS
·
Aug 21

Eli Lilly Revenue Jumps 48% as Mounjaro and Zepbound Sales Reach $14.9B

TradingKey
·
Aug 20

Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines

Reuters
·
Aug 20

Novonesis Expects Results from Weight-Loss Drug Supplement Study in 2027

Reuters
·
Aug 20